New stock news | Crystal Technology plans to list in Hong Kong within this year, CEO responds: Hong Kong is very important to the company.

Recently, there have been reports that artificial intelligence (AI) drug development company JingTai Technology plans to list in Hong Kong this year. JingTai Technology CEO Ma Jian declined to comment but stated that the Hong Kong Stock Exchange's launch of Chapter 18A and 18C is very important for the company, as Hong Kong is a cutting-edge market in terms of capitalization. In March of this year, when the Hong Kong Stock Exchange released the summary of its consultation on Chapter 18C for qualifying biotech companies, JingTai Technology was mentioned as having responded to the consultation. At that time, there were rumors that JingTai Technology was considering an IPO listing in Hong Kong under the new regulations of Chapter 18C, with the possibility of submitting the application as early as this year. In October 2021, there were also reports that JingTai Technology may have secretly submitted an application for listing with the US Securities and Exchange Commission (SEC), with Goldman Sachs as its underwriter, aiming to raise 400-500 million US dollars. However, the SEC raised concerns as JingTai Technology's use of AI in drug development involves sensitive medical data. It is understood that JingTai Technology has received multiple rounds of funding, with investors including Sequoia China, SoftBank Vision Fund, China Life Equity Investment, Hina Asia Ventures, ZhenFund, Wuyuan Capital, Neumann Capital, Artisan Partners, Ping An Capital, CICC Capital, CMB International Capital, Mirae Asset Global Investments, CITIC Securities Investment, CICC Capital, Haizhong Capital, Shunwei Capital, Fosun Capital, Parkway Fund, V Capital, Google, Fengrui Capital, Renren Company, and others.